Feb 28, 2019

Lyrica Side Effects Generic Name: pregabalin

Note: This document contains side effect information about pregabalin. Some of the dosage forms listed on this page may not apply to the brand name Lyrica.

In Summary

Common side effects of Lyrica include: infection, ataxia, blurred vision, constipation, diplopia, dizziness, drowsiness, fatigue, headache, peripheral edema, tremor, weight gain, visual field loss, accidental injury, and xerostomia. Other side effects include: abnormal gait, abnormality in thinking, amnesia, arthralgia, asthenia, cognitive dysfunction, confusion, edema, neuropathy, sinusitis, speech disturbance, vertigo, visual disturbance, myasthenia, amblyopia, increased appetite, and twitching. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to pregabalin: oral capsule, oral solution, oral tablet extended release
Along with its needed effects, pregabalin (the active ingredient contained in Lyrica) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking pregabalin:

Less Common

  • Difficult or labored breathing
  • tightness in the chest


  • Blistering, peeling, or loosening of the skin
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • chills
  • cough
  • diarrhea
  • difficulty with swallowing
  • dizziness
  • fast heartbeat
  • hives, itching, skin rash
  • joint or muscle pain
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • unusual tiredness or weakness
Some side effects of pregabalin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

  • Accidental injury
  • blurred vision
  • burning, tingling, numbness or pain in the hands, arms, feet, or legs
  • change in walking and balance
  • clumsiness
  • confusion
  • difficulty having a bowel movement
  • difficulty with speaking
  • double vision
  • dry mouth
  • false beliefs that cannot be changed by facts
  • fever
  • headache
  • hoarseness
  • increased appetite
  • lack of coordination
  • loss of memory
  • lower back or side pain
  • painful or difficult urination
  • poor insight and judgment
  • problems with memory or speech
  • rapid weight gain
  • sensation of pins and needles
  • shakiness
  • sleepiness
  • stabbing pain
  • trembling, or other problems with muscle control or coordination
  • trouble recognizing objects
  • trouble thinking and planning
  • unsteady walk
  • unusual drowsiness
  • unusual weight gain or loss

Less Common

  • Anxiety
  • bloated or feeling of fullness
  • chest pain
  • cold sweats
  • cool, pale skin
  • cough producing mucus
  • decrease or change in vision
  • depression
  • excess air or gas in the stomach or bowels
  • eye disorder
  • false or unusual sense of well-being
  • general feeling of discomfort or illness
  • increased hunger
  • loss of appetite
  • loss of bladder control
  • loss of consciousness
  • loss of strength or energy
  • muscle aches, twitching or jerking, or weakness
  • nausea
  • nervousness
  • nightmares
  • noisy breathing
  • pain
  • passing gas
  • rhythmic movement of the muscles
  • runny nose
  • seizures
  • shivering
  • slurred speech
  • sweating
  • trouble sleeping
  • twitching
  • uncontrolled eye movements
  • vomiting

For Healthcare Professionals

Applies to pregabalin: oral capsule, oral solution, oral tablet extended release


The most common adverse reactions to this drug are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and "thinking abnormal" (primarily difficulty with concentration/attention); the more commonly reported events in pediatric patients include increased weight and increased appetite.[Ref]

Nervous system

Among pediatric patients receiving this drug for the treatment of partial onset seizures, somnolence was reported in 21% of drug treated patients and 14% of placebo patients. It occurred more frequently at higher doses.[Ref]
Very common (10% or more): Dizziness (up to 37%), somnolence (up to 25%)

Common (1% to 10%): Neuropathy, ataxia, vertigo, incoordination, tremor, abnormal gait, headache, speech disorder, twitching
Uncommon (0.1% to 1%): Syncope, stupor, myoclonus, psychomotor hyperactivity, dyskinesia, dizziness postural, intention tremor, nystagmus, hyporeflexia, hyperesthesia, burning sensation, ageusia, malaise
Rare (less than 0.1%): Convulsions, parosmia, hypokinesia, dysgraphia, shock, circumoral paresthesia, dysarthria, hyperalgesia, hyperkinesia, hypokinesia, hypotonia, myoclonus, neuralgia cerebellar syndrome, cogwheel rigidity, coma, dysautonomiadystoniaencephalopathy, extrapyramidal syndrome, Guillain-Barre syndrome, hypalgesia, intracranial hypertensiontorticollis, trismus, peripheral neuritis[Ref]


Very common (10% or more): Peripheral edema (up to 12%)
Common (1% to 10%): Chest pain
Uncommon (0.1% to 1%): Hypotension, hypertension, hot flushes, flushing, peripheral coldness, heart failure, postural hypotension, syncope
Rare (less than 0.1%): ST depressed, ventricular fibrillation
Frequency not reported: PR interval prolongation[Ref]
In controlled clinical trials in adult patients, peripheral edema was reported in 6% of patients receiving this drug compared with 2% in the placebo group; 0.5% and 0.2% of patients withdrew due to peripheral edema in the drug treated group and the placebo group, respectively. 
Analyses of clinical trial ECG data has shown the mean PR interval increase was 3 to 6 msec at doses greater than or equal to 300 mg/day. Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or those taking other PR prolonging medications, although the number of patients in the study was not sufficient to draw a definitive conclusion.[Ref]


Common (1% to 10%): Confusion, euphoria, amnesia, nervousness, irritability, disorientation, insomnia, libido decreased, disturbance in attention, anxiety, depersonalization, stupor, abnormal thinking
Uncommon (0.1% to 1%): Cognitive disorder, mental impairment, abnormal dreams, agitation, apathy, aphasia, hallucinations, hostility
Rare (less than 0.1%): Delirium, delusions, manic reaction, paranoid reaction, personality disorder, psychotic depression, schizophrenic reaction, sleep disorder, disinhibition[Ref]


Uncommon (0.1% to 1%): Hypersensitivity
Rare (0.01% to 0.1%): Allergic reaction, anaphylactic reaction[Ref]


Symptoms of angioedema have included swelling of the face, mouth (tongue, lips, and gums), and neck (throat and larynx). There have also been reports of life-threatening angioedema with respiratory compromise requiring emergency treatment. Therapy should be discontinued immediately in patients with these symptoms. Caution is recommended if this drug is used in patients who have had a previous episode of angioedema. Patients who are taking other drugs associated with angioedema (e.g., angiotensin converting enzyme inhibitors [ACE inhibitors]) may be at increased risk of developing angioedema.[Ref]
Common (1% to 10%): Ecchymosis, pruritus
Uncommon (0.1% to 1%): Angioedema, rash papular, urticariahyperhidrosis, abscess, cellulitisalopeciadry skineczemahirsutism, skin ulcer, urticaria, vesiculobullous rash
Rare (less than 0.1%): Stevens Johnson syndrome, cold sweat, angioedema, exfoliative dermatitis, lichenoid dermatitis, melanosis, nail disorder, petechial rash, purpuric rash, pustular rash, skin atrophy, skin necrosis, skin nodule, subcutaneous nodule[Ref]


Common (1% to 10%): Dry mouth, constipation, nausea, vomiting, diarrhea, flatulence, abdominal distention, gastroenteritis
Uncommon (0.1% to 1%): Gastroesophageal reflux disease, salivary hypersecretion, hypoesthesia oral, cholecystitischolelithiasiscolitisdysphagiaesophagitisgastritis, GI hemorrhage, melena, mouth ulceration, pancreatitis, rectal hemorrhage, tongue edema
Rare (less than 0.1%): Ascites, granuloma[Ref]


Common (1% to 10%): Urinary incontinenceerectile dysfunctionimpotenceurinary frequency, urinary incontinence
Uncommon (0.1% to 1%): Sexual dysfunction, ejaculation delayed, dysmenorrhea, breast pain, anorgasmia, albuminuria, dysuriahematuria, kidney calculus, leukorrhea, menorrhagia, metrorrhagia, oliguria, urinary retention, urine abnormality, abnormal ejaculation, albuminuria, amenorrhea, dysmenorrhea, kidney calculus, menorrhagia, metrorrhagia, oliguria 
Rare (less than 0.1%): Breast discharge, breast enlargement, gynecomastia, pelvic pain, balanitis, bladder neoplasm, cervicitisdyspareuniaepididymitis, glomerulitis, ovarian disorder[Ref]


Uncommon (0.1% to 1%): Neutropenia, blood creatine phosphokinase increased, alanine aminotransferase increased, aspartate aminotransferase increased, platelet count decreased, blood creatinine increased, blood potassium decreased, deep thrombophlebitis
Rare (less than 0.1%): White blood cell count decreased, anemia, eosinophiliahypochromic anemialeukocytosis, leukopenia, lymphadenopathythrombocytopenia
Rare (0.01% to 0.1%): Myelofibrosispolycythemia, prothrombin decreased, purpura[Ref]


Very common (10% or more): Infection (up to 14%)
Common (1% to 10%): Influenza syndrome[Ref]


Common (1% to 10%): Myasthenia, muscle cramp, arthralgia, back pain, pain in limb, cervical spasm, leg cramps
Uncommon (0.1% to 1%): Joint swelling, myalgia, muscle twitchingneck pain, muscle stiffness, neck rigidity, arthrosis
Rare (less than 0.1%): Rhabdomyolysis, chondrodystrophy, generalized spasm[Ref]


Very common (10% or more): Visual field changes (13%)
Common (1% to 10%): Blurry vision, abnormal vision, diplopia, conjunctivitis
Uncommon (0.1% to 1%): Peripheral vision loss, visual disturbance, eye swelling, visual field defect, visual acuity reduced, eye pain, asthenopia, photopsia, photosensitivity reaction, dry eye, lacrimation increased, eye irritation, retinal vascular disorder, abnormality of accommodation, blepharitis, dry eyes, eye hemorrhage, hyperacusis, photophobia, retinal edema
Rare (0.01% to 0.1%): Vision loss, keratitis, oscillopsia, altered visual depth perception, mydriasis, strabismus, visual brightness, anisocoria, blindness, corneal ulcer, exophthalmos, extraocular palsy, iritis, keratitis, keratoconjunctivitis, miosis, mydriasis, night blindness, ophthalmoplegia, optic atrophy, papilledema, parosmia, ptosis, uveitis[Ref]


Common (1% to 10%): Asthenia, accidental injury, face edema, pain, otitis mediatinnitus
Uncommon (less than 0.1% to 1%): Generalized edema, pain, pyrexia, chills, thirst
Rare (0.01% to 0.1%): Retroperitoneal fibrosis, retinal vascular disorder, taste loss, taste perversion
Frequency not reported: Withdrawal effects following rapid discontinuation[Ref]
Some patients have reported withdrawal effects following abrupt/rapid discontinuation. These symptoms included insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea.[Ref]


Common (1% to 10%): Dyspnea, bronchitis, nasopharyngitis
Uncommon (0.1% to 1%): Epistaxis, cough, nasal congestion, rhinitis, snoring, nasal dryness
Rare (less than 0.1%): Pulmonary edema, throat tightness, apnea, atelectasis, bronchiolitis, hiccup, laryngismus, lung fibrosis, yawn[Ref]


Common (1% to 10%): Weight gain, edema, hypoglycemia, increased appetite
Uncommon (0.1% to 1%): Weight decreased, blood glucose increased
Rare (0.01% to 0.1%): Glucose tolerance decreased, urate crystalluria[Ref]


Uncommon (0.1% to 1%): Nephritis
Rare (0.01% to 0.1%): Acute kidney failure, pyelonephritis[Ref]


Postmarketing reports: Gynecomastia, breast enlargement


1. "Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group, New York, NY. 
2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
3. Cerner Multum, Inc. "Australian Product Information." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
Post Polio Litaff, Association A.C _APPLAC Mexico

Feb 27, 2019

History Through Our Eyes: Feb. 26, 1954, fighting polio

To help polio patients whose respiratory muscles were weakened, metal cylinders called "iron lungs" were developed to regulate breathing.

There was a time when the word “polio” struck terror in the hearts of families.
In the first half of the 20th century, polio — short for poliomyelitis — crippled tens of thousands of Canadians until a vaccine was introduced in 1955. The disease peaked in Canada in 1953 with nearly 9,000 cases and 500 deaths, according to the Canadian Public Health Association.
In severe cases, the disease attacks the central nervous system, resulting in paralysis and muscle weakness.
To help those whose respiratory muscles were weakened, large metal cylinders called “iron lungs” were developed to regulate breathing. On Feb. 26, 1954, the Canadian Legion presented the Children’s Memorial Hospital with a new iron lung, purchased with the proceeds of the legion’s March of Dimes.
The original caption of this photograph said, “This is one of the new iron lungs being used at the Children’s Memorial Hospital in the fight against polio. Grouped around Nurse M. Pinkerton are interested hospital patients.”
That same day, Feb. 26, there was a Mothers’ March on Polio in 12 Montreal communities. The march raised $13,000 for the fight against polio.
American medical researcher Jonas Salk created an injectable vaccine against polio that was introduced in Canada and the United States in 1955. An oral polio vaccine developed by Albert Sabin was introduced in 1961. The two vaccines have virtually eliminated polio from the world.


Post Polio Litaff, Association A.C _APPLAC Mexico

Polio Film


Entradas populares



México Post Polio Una Vida Un Camino Una Experiencia

Post Polio LITAFF A.C.

Postpoliolitaff.- Asociación Post Polio Litaff A.C Primera Organización oficial sobre Síndrome de Post Poliomielitis En México.

Polio y Efectos Secundarios SPP
- See more at: http://polioamigossinfronteras.blogspot.mx/#sthash.6PkHAkfM.dpuf


Salk Institute

Polio Video

Polio Lungs


Polio Reinders

March Of Dimes Polio History

Erradicación de La poliomielitis

Blog Archive

Search This Blog

No more Polio

Dr. Bruno